GDF15 reflects beta cell function in obese patients independently of the grade of impairment of glucose metabolism.
Adult
Biomarkers
/ blood
Blood Glucose
/ metabolism
Cross-Sectional Studies
Diabetes Mellitus, Type 2
/ blood
Female
Glucose Intolerance
/ blood
Glycated Hemoglobin
/ metabolism
Growth Differentiation Factor 15
/ blood
Humans
Insulin
/ blood
Insulin Resistance
Insulin-Secreting Cells
/ metabolism
Male
Middle Aged
Obesity
/ blood
Prognosis
Young Adult
Biomarker
Cardiovascular risk marker
Diabetes
Impaired glucose metabolism
Predictor
Journal
Nutrition, metabolism, and cardiovascular diseases : NMCD
ISSN: 1590-3729
Titre abrégé: Nutr Metab Cardiovasc Dis
Pays: Netherlands
ID NLM: 9111474
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
24
08
2018
revised:
17
11
2018
accepted:
27
12
2018
pubmed:
6
2
2019
medline:
18
12
2019
entrez:
6
2
2019
Statut:
ppublish
Résumé
Growth differentiation factor 15 (GDF15) is a strong predictor of cardiovascular morbidity and mortality found to be both marker and target of impaired glucose metabolism. GDF15 increases following glucose administration and is up-regulated in obesity and diabetes. We investigate here the relationship between GDF15 and beta cell function. In this cross-sectional study we evaluated GDF15 concentrations in 160 obese subjects (BMI 35-63 kg/m We conclude that in patients with severe obesity, GDF15 strongly relates to beta cell function and should be further investigated as a potential therapeutic target and biomarker guiding treatment options.
Sections du résumé
BACKGROUND AND AIMS
Growth differentiation factor 15 (GDF15) is a strong predictor of cardiovascular morbidity and mortality found to be both marker and target of impaired glucose metabolism. GDF15 increases following glucose administration and is up-regulated in obesity and diabetes. We investigate here the relationship between GDF15 and beta cell function.
METHODS AND RESULTS
In this cross-sectional study we evaluated GDF15 concentrations in 160 obese subjects (BMI 35-63 kg/m
CONCLUSION
We conclude that in patients with severe obesity, GDF15 strongly relates to beta cell function and should be further investigated as a potential therapeutic target and biomarker guiding treatment options.
Identifiants
pubmed: 30718144
pii: S0939-4753(18)30364-8
doi: 10.1016/j.numecd.2018.12.008
pii:
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
GDF15 protein, human
0
Glycated Hemoglobin A
0
Growth Differentiation Factor 15
0
Insulin
0
hemoglobin A1c protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
334-342Informations de copyright
Copyright © 2019 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.